TargetMol

Atomoxetine hydrochloride

Product Code:
 
TAR-T0869
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T0869-25mg25mg£103.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0869-50mg50mg£114.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0869-100mg100mg£132.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0869-200mg200mg£164.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Atomoxetine Hydrochloride is the hydrochloride salt of atomoxetine, a phenoxy-3-propylamine derivative and selective non-stimulant, norepinephrine reuptake inhibitor with cognitive-enhancing activity. Although its precise mechanism of action is unknown, atomoxetine appears to selectively inhibit the pre-synaptic norepinephrine transporter, resulting in inhibition of the presynaptic reabsorption of norepinephrine and prolongation of norepinephrine activity in the synaptic cleft. The effect on cognitive brain function may result in improved attention and decreased impulsivity and activity levels.
CAS:
82248-59-7
Formula:
C17H22ClNO
Molecular Weight:
291.82
Pathway:
Neuroscience; GPCR/G Protein
Purity:
0.998
SMILES:
Cl.CNCC[C@@H](Oc1ccccc1C)c1ccccc1
Target:
Dopamine Receptor; 5-HT Receptor; Norepinephrine

References

1. Bymaster FP, et al. Neuropsychopharmacology, 2002, 27(5), 699-711. 2. Zerbe RL, et al. J Pharmacol Exp Ther, 1985, 232(1), 139-143. 3. Wong DT, et al. J Pharmacol Exp Ther, 1982, 222(1), 61-65.